Introduction

• Market Expansion Driven by Tuberculosis Screening Initiatives: The global QuantiFERON-TB Gold test market is estimated at approximately USD 684 million in 2024 and is poised to reach around USD 1.26 billion by 2032, growing at a steady CAGR of nearly 7.9%. This growth reflects the rising global focus on early and accurate latent tuberculosis infection (LTBI) detection, particularly in high-risk populations.
  
• Technological Advancements Boosting Diagnostic Accuracy: Innovations in interferon-gamma release assay (IGRA) technology, combined with increased clinical adoption of blood-based TB testing over traditional skin tests, are significantly enhancing diagnostic precision. The QuantiFERON-TB Gold test is gaining traction for its ability to deliver reliable, single-visit results, especially in resource-limited or high-burden regions.
  
• Growing Global Health Policies Supporting Market Demand: Expanding government initiatives, international health guidelines, and strategic collaborations with diagnostic labs are contributing to the test’s growing adoption. As tuberculosis remains a top public health concern, particularly in emerging economies, the market is expected to experience sustained demand through the forecast period.

Gap Analysis – Global QuantiFERON-TB Gold Test Market

• Limited Access in Low-Income Regions: Despite its clinical accuracy, access to QuantiFERON-TB Gold testing remains limited in resource-constrained settings due to infrastructure, affordability, and lack of trained personnel.
  
• Low Awareness Among Primary Care Providers: There is a significant knowledge gap among frontline healthcare workers regarding the benefits and use cases of interferon-gamma release assays (IGRAs) over traditional tuberculin skin tests.
  
• Underutilization in High-Burden Countries: Many high TB-burden countries still rely on outdated or less sensitive diagnostics, delaying early detection and contributing to continued transmission.
  
• Integration Challenges with National TB Programs: Difficulty in aligning QuantiFERON-TB Gold tests with national tuberculosis control strategies and existing healthcare workflows hampers widespread adoption in public health settings.
  
• Lack of Pediatric and Immunocompromised Patient Data: Limited clinical data on the performance of the test in pediatric populations and immunocompromised patients restricts broader clinical confidence and application in these groups.
  
• High Cost Compared to Conventional Methods: The upfront cost of QuantiFERON testing remains a barrier for widespread use, especially in settings with limited reimbursement support or health insurance coverage.
  
• Need for Improved Supply Chain Efficiency: Delays in test kit distribution and lack of regional manufacturing units contribute to inconsistent availability in emerging markets.
  
• Insufficient Digital Integration for Test Management: Many diagnostic centers lack automated systems or digital platforms for managing and interpreting QuantiFERON-TB results efficiently, affecting turnaround time and accuracy.

Global QuantiFERON-TB Gold Test Market Breakdown by Segment

1. By Test Type
1.1. QuantiFERON-TB Gold In-Tube Test (QFT-GIT)
1.2. QuantiFERON-TB Gold Plus Test (QFT-Plus)

2. By Application
2.1. Latent Tuberculosis Infection (LTBI) Detection
2.2. Active Tuberculosis Detection

3. By End User
3.1. Hospitals
3.2. Diagnostic Laboratories
3.3. Clinics
3.4. Research Institutes

4. By Region – Global QuantiFERON-TB Gold Test Market

4.1. North America
 4.1.1. United States
 4.1.2. Canada

4.2. Europe
 4.2.1. Germany
 4.2.2. United Kingdom
 4.2.3. France
 4.2.4. Italy
 4.2.5. Spain
 4.2.6. Rest of Europe

4.3. Asia-Pacific
 4.3.1. China
 4.3.2. India
 4.3.3. Japan
 4.3.4. South Korea
 4.3.5. Australia
 4.3.6. Rest of Asia-Pacific

4.4. Latin America
 4.4.1. Brazil
 4.4.2. Mexico
 4.4.3. Rest of Latin America

4.5. Middle East and Africa
 4.5.1. United Arab Emirates
 4.5.2. Saudi Arabia
 4.5.3. South Africa
 4.5.4. Rest of Middle East and Africa

5. Key Players – Global QuantiFERON-TB Gold Test Market
5.1. Qiagen N.V.
5.2. Hologic, Inc.
5.3. Abbott Laboratories
5.4. Thermo Fisher Scientific Inc.
5.5. Bio-Rad Laboratories, Inc.
5.6. Meridian Bioscience, Inc.
5.7. Oxford Immunotec Global PLC
5.8. Cellestis Limited (a Qiagen Company)
5.9. Dynex Technologies, Inc.
5.10 Others